angioedema – what you need to know
TRANSCRIPT
![Page 1: Angioedema – What You Need to Know](https://reader031.vdocument.in/reader031/viewer/2022020913/62035ec536ea5041ce3c8e37/html5/thumbnails/1.jpg)
ANGIOEDEMA –WHAT YOU NEED TO KNOW
K IMBERLY HULL DO
![Page 2: Angioedema – What You Need to Know](https://reader031.vdocument.in/reader031/viewer/2022020913/62035ec536ea5041ce3c8e37/html5/thumbnails/2.jpg)
No relevant disclosures
![Page 3: Angioedema – What You Need to Know](https://reader031.vdocument.in/reader031/viewer/2022020913/62035ec536ea5041ce3c8e37/html5/thumbnails/3.jpg)
OBJECTIVES
Review the etiologies of angioedema without
urticaria
Discuss the diagnostic approach to angioedema
Discuss acute and chronic management strategies
of angioedema
![Page 4: Angioedema – What You Need to Know](https://reader031.vdocument.in/reader031/viewer/2022020913/62035ec536ea5041ce3c8e37/html5/thumbnails/4.jpg)
INITIAL EVALUATION
![Page 5: Angioedema – What You Need to Know](https://reader031.vdocument.in/reader031/viewer/2022020913/62035ec536ea5041ce3c8e37/html5/thumbnails/5.jpg)
HISTORY
Presence/absence of urticaria
Associated systemic findingsShortness of breath
Abdominal pain and cramping
Distal extremity edema
History of food or medication allergies
Known history of malignancy
Family history
![Page 6: Angioedema – What You Need to Know](https://reader031.vdocument.in/reader031/viewer/2022020913/62035ec536ea5041ce3c8e37/html5/thumbnails/6.jpg)
EXAMINATION OF THE EYES
Eyes
Lips
Tongue
Lymph nodes
Extremities
Abdomen
Larynx
![Page 7: Angioedema – What You Need to Know](https://reader031.vdocument.in/reader031/viewer/2022020913/62035ec536ea5041ce3c8e37/html5/thumbnails/7.jpg)
EXAMINATION OF THE ORAL CAVITY
Eyes
Lips
Tongue
Lymph nodes
Extremities
Abdomen
Larynx
![Page 8: Angioedema – What You Need to Know](https://reader031.vdocument.in/reader031/viewer/2022020913/62035ec536ea5041ce3c8e37/html5/thumbnails/8.jpg)
EXAMINATION OF THE ORAL CAVITY
Eyes
Lips
Tongue
Lymph nodes
Extremities
Abdomen
Larynx
![Page 9: Angioedema – What You Need to Know](https://reader031.vdocument.in/reader031/viewer/2022020913/62035ec536ea5041ce3c8e37/html5/thumbnails/9.jpg)
EXAMINATION OF THE LYMPH NODES
Eyes
Lips
Tongue
Lymph nodes
Extremities
Abdomen
Larynx
![Page 10: Angioedema – What You Need to Know](https://reader031.vdocument.in/reader031/viewer/2022020913/62035ec536ea5041ce3c8e37/html5/thumbnails/10.jpg)
EXAMINATION OF THE EXTREMITIES
Eyes
Lips
Tongue
Lymph nodes
Extremities
Abdomen
Larynx
![Page 11: Angioedema – What You Need to Know](https://reader031.vdocument.in/reader031/viewer/2022020913/62035ec536ea5041ce3c8e37/html5/thumbnails/11.jpg)
EXAMINATION OF THE ABDOMEN
Eyes
Lips
Tongue
Lymph nodes
Extremities
Abdomen
Larynx
![Page 12: Angioedema – What You Need to Know](https://reader031.vdocument.in/reader031/viewer/2022020913/62035ec536ea5041ce3c8e37/html5/thumbnails/12.jpg)
EXAMINATION OF THE LARYNX
Eyes
Lips
Tongue
Lymph nodes
Extremities
Abdomen
Larynx
![Page 13: Angioedema – What You Need to Know](https://reader031.vdocument.in/reader031/viewer/2022020913/62035ec536ea5041ce3c8e37/html5/thumbnails/13.jpg)
CLINICAL FEATURES OF ANGIOEDEMA
Recurrent, nonpitting, nonpruritic, nonurticarial edema
Main sites of cutaneous involvement: face, hands, arms, legs, genitalia, and buttocks
Abdominal pain → Nausea/Vomiting → Surgical abdomen
Laryngeal edema → Asphyxia
May persist for 2 to 5 days
Attacks are triggered by trauma, pressure, stress, menstruation, ovulation, or infectious diseases
![Page 14: Angioedema – What You Need to Know](https://reader031.vdocument.in/reader031/viewer/2022020913/62035ec536ea5041ce3c8e37/html5/thumbnails/14.jpg)
PITFALL
Erythemamarginatum
![Page 15: Angioedema – What You Need to Know](https://reader031.vdocument.in/reader031/viewer/2022020913/62035ec536ea5041ce3c8e37/html5/thumbnails/15.jpg)
DIFFERENTIAL DIAGNOSIS
Allergic contact dermatitis
Ludwig angina
Quincke’s disease
Granulomatous cheilitis
Facial cellulitis
Dermatomyositis
Crohn’s disease
![Page 16: Angioedema – What You Need to Know](https://reader031.vdocument.in/reader031/viewer/2022020913/62035ec536ea5041ce3c8e37/html5/thumbnails/16.jpg)
ANGIOEDEMA WITH URTICARIA
Acute urticaria
Physical urticaria
Urticarial vasculitis
Episodic angioedema with eosinophilia
![Page 17: Angioedema – What You Need to Know](https://reader031.vdocument.in/reader031/viewer/2022020913/62035ec536ea5041ce3c8e37/html5/thumbnails/17.jpg)
ANGIOEDEMA WITHOUT URTICARIA
Hereditary angioedema
• Type I
• Type II
• Type III
Acquired angioedema
Angioedema due to ACE Inhibitors
![Page 18: Angioedema – What You Need to Know](https://reader031.vdocument.in/reader031/viewer/2022020913/62035ec536ea5041ce3c8e37/html5/thumbnails/18.jpg)
DIAGNOSIS
Plasma C4 level
Normal value essentially excludes HAE
Low C4 levels should prompt further investigation
Plasma C1 inhibitor assays
Functional
Quantitative
Plasma C1q levels
Low in acquired angioedema
![Page 19: Angioedema – What You Need to Know](https://reader031.vdocument.in/reader031/viewer/2022020913/62035ec536ea5041ce3c8e37/html5/thumbnails/19.jpg)
Plasmin FXIIa
KallikreinC1q
C1r C1s
C5
convertase
C5b
C6
C7
C8
C9
C4, C2
C5
C3a
C3b
C3
C5aIncreased vascular
permeability
ANGIOEDEMA
HMWK
Bradykinin
C1 INH
![Page 20: Angioedema – What You Need to Know](https://reader031.vdocument.in/reader031/viewer/2022020913/62035ec536ea5041ce3c8e37/html5/thumbnails/20.jpg)
HEREDITARY ANGIOEDEMA TYPE I
Autosomal dominant
20-25% spontaneous mutation
Accounts for 80-85% of cases
Low functional plasma levels of a normal C1
esterase inhibitor protein
![Page 21: Angioedema – What You Need to Know](https://reader031.vdocument.in/reader031/viewer/2022020913/62035ec536ea5041ce3c8e37/html5/thumbnails/21.jpg)
HEREDITARY ANGIOEDEMA TYPE II
Autosomal dominant
Accounts for 15-20% of cases
Two variants
Functionally inactive protein present in normal amounts
Nonfunctioning inhibitor present in increased amounts
![Page 22: Angioedema – What You Need to Know](https://reader031.vdocument.in/reader031/viewer/2022020913/62035ec536ea5041ce3c8e37/html5/thumbnails/22.jpg)
HEREDITARY ANGIOEDEMA TYPE III
Predominantly in females
Normal quantitative and functional C1 INH and C4
levels
Missense mutation in Factor XII
Excessive bradykinin formation
Family history
![Page 23: Angioedema – What You Need to Know](https://reader031.vdocument.in/reader031/viewer/2022020913/62035ec536ea5041ce3c8e37/html5/thumbnails/23.jpg)
ACQUIRED ANGIOEDEMA
C1-INH deficiency due to increased C1-INH
catabolism
C1q is usually decreased
AA Type I may be presenting feature of underlying
lymphoreticular disease
AA Type II may be due to an autoantibody
directed against C1-INH
![Page 24: Angioedema – What You Need to Know](https://reader031.vdocument.in/reader031/viewer/2022020913/62035ec536ea5041ce3c8e37/html5/thumbnails/24.jpg)
ACE INHIBITOR ASSOCIATED ANGIOEDEMA
ACE inhibitors interfere with the degradation of
bradykinin
Most commonly involves the face and tongue;
rarely the bowel and extremities
Most frequently occurs within the first month of
therapy
Increased risk in African-Americans
![Page 25: Angioedema – What You Need to Know](https://reader031.vdocument.in/reader031/viewer/2022020913/62035ec536ea5041ce3c8e37/html5/thumbnails/25.jpg)
Diagnosis C4 C1 Inhibitor Function C1 Inhibitor Level C1q
HAE Type 1 Low Low Low Normal
HAE Type II Low Low Normal Normal
HAE Type III Normal Normal Normal Normal
AAE Low Low Normal/Low Low
ACE inhibitor-
associated
angioedema
Normal Normal Normal Normal
![Page 26: Angioedema – What You Need to Know](https://reader031.vdocument.in/reader031/viewer/2022020913/62035ec536ea5041ce3c8e37/html5/thumbnails/26.jpg)
INITIAL MANAGEMENT
Intubation or tracheostomy for serious respiratory obstruction
Blood pressure monitoring
Subcutaneous adrenaline (0.3 mg every 10 minutes) may be helpful
Intravenous fresh frozen plasma or C1 inhibitor concentrate
Antihistamines and corticosteroids are ineffective
![Page 27: Angioedema – What You Need to Know](https://reader031.vdocument.in/reader031/viewer/2022020913/62035ec536ea5041ce3c8e37/html5/thumbnails/27.jpg)
MAINTENANCE THERAPY
Attenuated androgens
Danazol
Stanozolol
Oxandrolone
Antifibrinolytic agents
ϵ-Aminocaproic acid
Tranexamic acid
Coadministration of ACE inhibitors and estrogens is
contraindicated
![Page 28: Angioedema – What You Need to Know](https://reader031.vdocument.in/reader031/viewer/2022020913/62035ec536ea5041ce3c8e37/html5/thumbnails/28.jpg)
NEW THERAPIES
Cinryze
Berinert
Ruconest
Ecallantide
Icatibant
![Page 29: Angioedema – What You Need to Know](https://reader031.vdocument.in/reader031/viewer/2022020913/62035ec536ea5041ce3c8e37/html5/thumbnails/29.jpg)
C1 ESTERASE INHIBITORS
Cinryze
Human derived, nano filtered C1 esterase inhibitor
concentrate
Approved by the FDA in 2008 for prophylaxis of HAE attacks
Reported to be effective in acute attacks
Patient self-administration after proper training by a
healthcare professional
![Page 30: Angioedema – What You Need to Know](https://reader031.vdocument.in/reader031/viewer/2022020913/62035ec536ea5041ce3c8e37/html5/thumbnails/30.jpg)
C1 ESTERASE INHIBITORS
Berinert
Human derived C1 esterase inhibitor concentrate
FDA approved in 2009 for acute abdominal and facial
angioedema attacks in patients with HAE
FDA approved in 2012 for laryngeal angioedema
Patient self-administration after proper training by a
healthcare professional
![Page 31: Angioedema – What You Need to Know](https://reader031.vdocument.in/reader031/viewer/2022020913/62035ec536ea5041ce3c8e37/html5/thumbnails/31.jpg)
C1 ESTERASE INHIBITORS
Ruconest
Recombinant C1 esterase inhibitor concentrate
FDA approved in 2014 for acute attacks of HAE
Contraindicated in patients with a history of allergy to
rabbits
Patient self-administration after proper training by a
healthcare professional
![Page 32: Angioedema – What You Need to Know](https://reader031.vdocument.in/reader031/viewer/2022020913/62035ec536ea5041ce3c8e37/html5/thumbnails/32.jpg)
KALLIKREIN INHIBITOR
Ecallantide
Recombinant peptide produced in Pichia pastoris yeast
Selective, reversible inhibitor of plasma kallikrein
Approved by the FDA in 2009 for the treatment of acute
attacks of HAE
Inhibits the production of bradykinin
Black box warning – development of antidrug antibodies
leading to anaphylactic-like reactions
![Page 33: Angioedema – What You Need to Know](https://reader031.vdocument.in/reader031/viewer/2022020913/62035ec536ea5041ce3c8e37/html5/thumbnails/33.jpg)
BRADYKININ ANTAGONIST
Icatibant
Selective bradykinin B2 receptor antagonist
FDA approved in 2011 for treatment of acute attacks of HAE
May potentially have a pharmacodynamic interaction with
ACE inhibitors - may attenuate antihypertensive effect
![Page 34: Angioedema – What You Need to Know](https://reader031.vdocument.in/reader031/viewer/2022020913/62035ec536ea5041ce3c8e37/html5/thumbnails/34.jpg)
![Page 35: Angioedema – What You Need to Know](https://reader031.vdocument.in/reader031/viewer/2022020913/62035ec536ea5041ce3c8e37/html5/thumbnails/35.jpg)
![Page 36: Angioedema – What You Need to Know](https://reader031.vdocument.in/reader031/viewer/2022020913/62035ec536ea5041ce3c8e37/html5/thumbnails/36.jpg)
SUMMARY
Understanding the causes of angioedema without urticaria is a must
Ask the right questions
Be systematic in your work-up
Chronic management of angioedema can be managed by medical dermatology
Be confident in your knowledge and skills
![Page 37: Angioedema – What You Need to Know](https://reader031.vdocument.in/reader031/viewer/2022020913/62035ec536ea5041ce3c8e37/html5/thumbnails/37.jpg)